This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
SAN DIEGO, Jan. 9, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system disorders and pain, and Mallinckrodt (NYSE:MNK) announced today that the co-promotion of SUMAVEL
® (sumatriptan injection) Needle-free Delivery System will end on January 31, 2014. SUMAVEL DosePro is Zogenix's first commercial product and was launched in January 2010 for the acute treatment of migraine and cluster headache.
Beginning February 1, 2014, Zogenix will assume full responsibility for the continued commercialization of the brand, with a focus on headache specialists, pain specialists and neurologists who treat a significant number of migraine patients. The early termination of the co-promotion by five months, originally scheduled to end on June 30, 2014, is timed to precede the previously disclosed expansion of the Zogenix sales force planned in February 2014.
The companies have agreed to a detailed customer transition plan with a goal of uninterrupted access and service to prescribers of SUMAVEL DosePro.
Under the amended co-promotion agreement, neither company will incur any penalty payments related to the early termination of the agreement which was originally slated to expire June 30, 2014. Mallinckrodt will continue to earn a service fee based on product sales to its physician segment through January 31, 2014. Zogenix will no longer pay service fees to Mallinckrodt for sales of SUMAVEL DosePro beginning February 1, 2014.
About SUMAVEL DosePro INDICATION and IMPORTANT LIMITATIONS
Sumavel DosePro (sumatriptan injection) is a serotonin (5-HT
1B/1D) receptor agonist (triptan) indicated for the acute treatment of migraine with or without aura in adults and the acute treatment of cluster headache in adults.
Limitations of Use
SUMAVEL DosePro is intended for use only if a clear diagnosis of migraine or cluster headache has been established. If a patient has no response to the first migraine attack treated with SUMAVEL DosePro, reconsider the diagnosis of migraine before SUMAVEL DosePro is administered to treat any subsequent attacks. SUMAVEL DosePro is not indicated for the prevention of migraine attacks.